KANUMA 2 mg/ml concentrate for solution for infusion
Authorisation EU/1/15/1033/001 · Alexion Europe SAS
- Licence holder
- Alexion Europe SAS (all products →)
- Active substance
- Sebelipase alfa
- Dosage form
- Concentrate for solution for infusion
- Route of administration
- Intravenous use
- ATC codes
- A16AB, A16AB14
- First authorised
- 28/08/2015
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- New active substance (Article 8(3) of Directive No 2001/83/EC)
Sebelipase alfa: supply and approvals
1 authorised product on the HPRA list contains Sebelipase alfa. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 19 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 19 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 19 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 1033. It has been authorised for 11 years (since 28 August 2015). The HPRA list does not say whether it is on sale.
Other medicines with Sebelipase alfa in Ireland
No other product on the HPRA list contains Sebelipase alfa.
Other substances in ATC group A16AB
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 11 other active substances share the group A16AB with this product:
Imiglucerase (3) · Asfotase alfa (2) · Laronidase (1) · Cerliponase (1) · Pegunigalsidase Alfa (1) · Protein c agalsidase beta (recombinant human-a-galactoside a) (1) · Velmanase alfa (1) · Alglucosidase alfa (1) · Cipaglucosidase alfa (1) · Agalsidase alfa (1) · Olipudase Alfa (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Alexion Europe SAS holds 4 products on the HPRA list, with 3 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.